Table 1.
Clinical trials of platinum-based agents and PARP inhibitors
| Clinical Trial ID | Study Name | Conditions (cancer or disease) | PARP inhibitor used | Platinum-based agent used | Other agent used | |
|---|---|---|---|---|---|---|
| 1. | NCT00516724 | Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination with Carboplatin and/or Paclitaxel | Triple negative metastatic breast cancer and advanced ovarian cancer | Olaparib | Carboplatin | Paclitaxel |
| 2. | NCT01237067 | Olaparib in Combination with Carboplatin for Refractory or Recurrent Women’s Cancers | Cervical, ovarian, fallopian tube, breast, endometrial and primary peritoneal carcinoma | Olaparib | Carboplatin | |
| 3. | NCT01445418 | AZD2281 Plus Carboplatin to Treat Breast and Ovarian Cancer | Breast and ovarian cancer | Olaparib | Carboplatin | |
| 4. | NCT01081951 | Study to Compare the Efficacy and Safety of Olaparib When Given in Combination with Carboplatin and Paclitaxel, Compared with Carboplatin and Paclitaxel in Patients with Advanced Ovarian Cancer | Ovarian cancer | Olaparib | Carboplatin | Paclitaxel |
| 5. | NCT02033551 | A Study Evaluating Veliparib as a Single Agent or in Combination with Chemotherapy in Subjects with Solid Tumors | Breast, ovarian, colon, lung and gastric cancer; solid tumors | Veliparib | Carboplatin | Paclitaxel, FOLFIRI |
| 6. | NCT01063816 | A Study of ABT-888 in Combination with Carboplatin and Gemcitabine in Subjects with Advanced Solid Tumors | Advanced solid tumors | Veliparib | Carboplatin | Gemcitabine |
| 7. | NCT01459380 | Veliparib, Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, and Bevacizumab in Treating Patients with Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer | Ovarian tumors: malignant, mixed epithelial tumor, clear cell cystadenocarcinoma, endometrioid adenocarcinoma, serous cystadenocarcinoma, recurrent carcinoma, undifferentiated carcinoma; recurrent fallopian tube and recurrent primary peritoneal carcinoma | Veliparib | Carboplatin | Bevacizumab, pegylated liposomal doxorubicin hydrochloride |
| 8. | NCT01251874 | Veliparib and Carboplatin in Treating Patients with HER2-Negative Metastatic Breast Cancer | Breast cancer: BRCA1 or BRCA2 mutation carrier, estrogen receptor negative/positive, HER2/Neu negative, male breast carcinoma, progesterone receptor negative/positive, stage IIIB/IIIC/IV breast cancer, triple-negative carcinoma | Veliparib | Carboplatin | |
| 9. | NCT01149083 | Veliparib with or without Carboplatin in Treating Patients with Stage III or Stage IV Breast Cancer | Breast cancer: BRCA1/BRCA2 mutation carrier, recurrent breast carcinoma, stage IIIB/IIIC/IV breast cancer | Veliparib | Carboplatin | |
| 10. | NCT00588991 | Veliparib and Topotecan with or without Carboplatin in Treating Patients with Relapsed or Refractory Acute Leukemia, High-Risk Myelodysplasia, or Aggressive Myeloproliferative Disorders | Adult acute leukemia – subtypes: megakaryoblastic, monoblastic, monocytic, myeloid with Inv(16)(p13.1q22), CBFB-MYH11, myeloid with maturation, myeloid with minimal differentiation, myeloid with t(16;16)(p13.1;q22), CBFB-MYH11, myeloid with t(8;21)(q22;q22), RUNX1-RUNX1T1, myeloid with t(9;11)(p22;q23), MLLT3-MLL, myeloid leukemia without maturation, myelomonocytic leukemia; adult erythroleukemia; adult pure erythroid leukemia; chronic myelomonocytic leukemia; de novo myelodysplastic syndrome; essential thrombocythemia; hematopoietic and lymphoid cell neoplasm; Philadelphia chromosome negative; BCR-ABL1 positive chronic myelogenous leukemia; polycythemia vera; previously treated myelodysplastic syndrome; recurrent adult acute lymphoblastic leukemia; recurrent adult acute myeloid leukemia; recurrent disease; secondary myelodysplastic syndrome | Veliparib | Carboplatin | Topotecan |
| 11. | NCT02483104 | Veliparib in Combination with Carboplatin and Weekly Paclitaxel in Japanese Subjects with Ovarian Cancer | Ovarian cancer | Veliparib | Carboplatin | Paclitaxel |
| 12. | NCT02106546 | Randomized, Double-Blind, Multicenter, Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Previously Untreated Advanced or Metastatic Squamous Non-Small Cell Lung Cancer | Lung cancer – squamous non-small cell | Veliparib | Carboplatin | Paclitaxel |
| 13. | NCT01009190 | A Study of Poly (ADP-Ribose) Polymerase Inhibitor PF-01367338 In Combination with Several Chemotherapeutic Regimens | Advanced solid tumors | PF-1367338 | Carboplatin | |
| 14. | NCT01560104 | A Clinical Study Conducted in Multiple Centers Comparing Veliparib in Combination with Carboplatin and Paclitaxel Versus a Placebo in Combination with Carboplatin and Paclitaxel in Patients with Advanced Non-small Cell Lung Cancer | Lung cancer – non-small cell | Veliparib | Carboplatin | Paclitaxel |
| 15. | NCT01281150 | Veliparib in Combination with Carboplatin and Paclitaxel in Treating Patients with Locally Advanced or Metastatic Solid Tumors | Breast cancer: adult solid neoplasm, estrogen receptor negative/positive, HER2/Neu negative, male breast carcinoma, progesterone receptor negative, recurrent breast carcinoma, triple-negative, stage IIIB/IIIC/IV breast cancer | Veliparib | Carboplatin | Paclitaxel |
| 16. | NCT00535119 | Veliparib, Carboplatin, and Paclitaxel in Treating Patients with Advanced Solid Cancer | Adult solid neoplasm, BRCA1/BRCA2mutation carrier, hereditary breast and ovarian cancer syndrome | Veliparib | Carboplatin | Paclitaxel |
| 17. | NCT01045304 | Study of SAR240550 (BSI-201) in Combination with Gemcitabine/Carboplatin, in Patients with Metastatic Triple Negative Breast Cancer | Breast cancer – metastatic | Iniparib | Carboplatin | Gemcitabine |
| 18. | NCT00687687 | Evaluation of Paclitaxel (Taxol, NSC #673089), Carboplatin (Paraplatin, NSC #241240), and BSI-201 (NSC #746045, IND #71,677) in the Treatment of Advanced, Persistent, or Recurrent Uterine Carcinosarcoma | Uterine carcinosarcoma | BSI-201 | Carboplatin | Paclitaxel |
| 19. | NCT00540358 | A Phase 2 Trial of Standard Chemotherapy, with or without BSI-201, in Patients with Triple Negative Metastatic Breast Cancer | Breast cancer | Iniparib | Carboplatin | Gemcitabine |
| 20. | NCT00938652 | A Phase 3, Multi-Center Study of Gemcitabine/Carboplatin, with or without BSI-201, in Patients with ER-, PR-, and Her2-Negative Metastatic Breast Cancer | Breast cancer | Iniparib | Carboplatin | Gemcitabine |
| 21. | NCT01455532 | A Dose Escalation Study of Iniparib as a Single Agent and in Combination in Solid Tumors | Neoplasm malignant | Iniparib | Carboplatin | Gemcitabine |
| 22. | NCT01213381 | Safety and Pharmacokinetics of SAR240550 (BSI-201) Twice Weekly in Patients with Advanced Solid Tumors | Advance solid tumors | Iniparib | Carboplatin | Gemcitabine |
| 23. | NCT02163694 | A Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel with or without Veliparib (ABT-888) in HER2-negative Metastatic or Locally Advanced Unresectable BRCA-associated Breast Cancer | Breast cancer – metastatic | Veliparib | Carboplatin | Paclitaxel, placebo |
| 24. | NCT02470585 | Veliparib with Carboplatin and Paclitaxel and as Continuation Maintenance Therapy in Subjects with Newly Diagnosed Stage III or IV, High-grade Serous, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | Ovarian cancer/neoplasm | Veliparib | Carboplatin | Paclitaxel |
| 25. | NCT02412371 | A Study Evaluating the Efficacy and Tolerability of Veliparib in Combination with Paclitaxel/Carboplatin-Based Chemoradiotherapy Followed by Veliparib and Paclitaxel/Carboplatin Consolidation in Subjects with Stage III Non-Small Cell Lung Cancer | Lung cancer – non-small cell stage III | Veliparib | Carboplatin | Paclitaxel |
| 26. | NCT01366144 | Veliparib, Paclitaxel, and Carboplatin in Treating Patients with Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction | Bladder, breast, unknown primary origin, endometrial, esophageal, lung, renal pelvis urothelial, ureter urothelial and urethral carcinoma; malignant head and neck neoplasm; melanoma; ovarian neoplasm; testicular lymphoma | Veliparib | Carboplatin | Paclitaxel |
| 27. | NCT02289690 | Dose Escalation and Double-blind Study of Veliparib in Combination with Carboplatin and Etoposide in Treatment-Naive Extensive Stage Disease Small Cell Lung Cancer | Lung cancer – small cell | Veliparib | Carboplatin | Etoposide |
| 28. | NCT01082549 | Trial of Gemcitabine/Carboplatin with or without Iniparib (SAR240550) (a PARP1 Inhibitor) in Subjects with Previously Untreated Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) | Lung cancer – squamous cell | Iniparib | Carboplatin | Gemcitabine |
| 29. | NCT00813956 | A Phase 2 Study of Standard Chemotherapy Plus BSI-201 (a PARP Inhibitor) in the Neoadjuvant Treatment of Triple Negative Breast Cancer | Breast cancer – triple negative | BSI-201 | Carboplatin | Gemcitabine |
| 30. | NCT01711541 | Combination Chemotherapy with or without Veliparib in Treating Patients with Stage IV Head and Neck Cancer | Human papillomavirus infection; salivary gland squamous cell carcinoma stage IVA/IVB laryngeal/hypopharyngeal/lip and oral cavity/nasal cavity and paranasal sinus squamous cell carcinoma; stage IVA/IVB major salivary gland carcinoma, tongue carcinoma | Veliparib | Carboplatin, Cisplatin | Fluorouracil, hydroxyurea, paclitaxel |
| 31. | NCT00989651 | Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients with Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer | Fallopian tube: clear cell, endometrioid, mucinous and undifferentiated adenocarcinoma; carcinosarcoma; serous neoplasm; transitional cell carcinoma; Cancer stage IIA/IIB/IIC,IIIA/IIIB/IV Ovarian: Brenner tumor; carcinosarcoma; clear cell, endometrioid, mucinous, serous and undifferentiated adenocarcinoma; mixed epithelial tumor; transitional cell carcinoma; cancer stage IIA/IIB/IIC,IIIA/IIIB/IV; primary peritoneal serous adenocarcinoma stage IIIA/IIIB/IIIC/IV primary peritoneal cancer |
Veliparib | Carboplatin, Cisplatin | Bevacizumab |
| 32. | NCT02264990 | Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Investigator’s Choice of Standard Chemotherapy in Subjects Receiving First Cytotoxic Chemotherapy for Metastatic or Advanced Non-Squamous Non-Small Cell Lung Cancer Who Are Current or Former Smokers | Lung cancer – non-squamous non-small cell | Veliparib | Carboplatin, Cisplatin | Paclitaxel, pemetrexed |
| 33. | NCT00422682 | A Study Evaluating BSI-201 in Combination with Chemotherapeutic Regimens in Subjects with Advanced Solid Tumors | Tumors | BSI-201 | Carboplatin, Temozolomide | Topotecan, gemcitabine, paclitaxel |
| 34. | NCT01506609 | The Study Evaluating Efficacy and Tolerability Of Veliparib in Combination with Temozolomide or In Combination with Carboplatin and Paclitaxel Versus Placebo in Subjects with BRCA1 and BRCA2 Mutation and Metastatic Breast Cancer | Breast cancer – metastatic | Veliparib | Carboplatin, Temozolomide | Paclitaxel |
| 35. | NCT01074970 | PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-) with BRCA1/2 Mutations | Breast cancer | Rucaparib | Cisplatin | |
| 36. | NCT01642251 | Cisplatin and Etoposide with or without Veliparib in Treating Patients with Extensive Stage Small Cell Lung Cancer or Metastatic Large Cell Neuroendocrine Non-small Cell Lung Cancer | Carcinoma: unknown primary origin, extensive stage small cell lung, large cell lung, neuroendocrine, newly diagnosed of unknown primary origin, stage IV non-small cell lung | Veliparib | Cisplatin | Etoposide |
| 37. | NCT01281852 | Paclitaxel, Cisplatin, and Veliparib in Treating Patients with Advanced, Persistent, or Recurrent Cervical Cancer | Cervical cancer: adenocarcinoma, adenosquamous, squamous cell, recurrent, stage IVB | Veliparib | Cisplatin | Paclitaxel |
| 38. | NCT01104259 | Veliparib, Cisplatin, and Vinorelbine Ditartrate in Treating Patients with Recurrent and/or Metastatic Breast Cancer | Breast cancer: estrogen receptor-negative, HER2-negative, hereditary breast/ovarian cancer – BRCA1/BRCA2, male breast cancer, progesterone receptor-negative, recurrent, stage IV, triple-negative | Veliparib | Cisplatin | Vinorelbine tartrate |
| 39. | NCT00678132 | AZD2281 and Cisplatin Plus Gemcitabine to Treat Solid Tumor Cancers | Neoplasms | Olaparib | Cisplatin | Gemcitabine |
| 40. | NCT01086254 | SAR240550 in Combination with Gemcitabine/Cisplatin in Non-small Cell Lung Cancer | Lung cancer – non-small cell stage IV | Iniparib | Cisplatin | Gemcitabine |
| 41. | NCT01345357 | Study of CEP-9722 in Combination with Gemcitabine and Cisplatin in Patients with Advanced Solid Tumors or Mantle Cell Lymphoma | Solid tumors or mantle cell lymphoma | CEP-9722 | Cisplatin | Gemcitabine |
| 42. | NCT02723864 | Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination with Cisplatin in People with Refractory Solid Tumors | Neoplasms | Veliparib | Cisplatin | VX-970 |
| 43. | NCT02595905 | Cisplatin with or without Veliparib in Treating Patients with Stage IV Triple-Negative and/or BRCA Mutation-Associated Breast Cancer | Breast cancer: BRCA1/BRCA2 mutation carrier, estrogen receptor negative, HER2/Neu negative, progesterone receptor negative, stage IV, triple-negative | Veliparib | Cisplatin | |
| 44. | NCT02308072 | Phase I Study of Olaparib Combined with Cisplatin-based Chemoradiotherapy to Treat Locally Advanced Head and Neck Cancer | Head and neck cancer | Olaparib | Cisplatin | |
| 45. | NCT01585805 | Gemcitabine Hydrochloride and Cisplatin with or without Veliparib or Veliparib Alone in Treating Patients with Locally Advanced or Metastatic Pancreatic Cancer | Breast cancer: BRCA1/BRCA2 mutation carrier; pancreatic cancer: non-metastatic, metastatic, recurrent, stage III, stage IV | Veliparib | Cisplatin | Gemcitabine |
Source: www.clinicaltrials.gov